Imported generic drugs will face zero tariffs for two years starting August 1 before escalating to a 100% levy in 2028 and 200% in 2029. The phased schedule for generic drug tariffs aims to force manufacturers to build U.S. pharmaceutical production facilities, but industry experts warn the economics remain deeply challenging.
President Donald Trump announced the escalation as a penalty for companies that fail to move operations onshore during the grace period. The directive underscores a broader goal to reshore low-cost drug manufacturing. According to Legis1, a congressional intelligence platform, nearly all prescriptions filled in the U.S. rely on generic drugs manufactured overseas. These imports often involve complex ownership structures and fragmented supply chains. Shifting this massive volume of low-cost medicine production to domestic soil would require unprecedented capital investment and a specialized workforce that currently does not exist at the required scale.
The Math of Reshoring U.S. Pharmaceutical Production
Deborah Elms, head of trade policy at the Hinrich Foundation, notes that building pharmaceutical production in the U.S. is complex and expensive. “I am not sure that even a potential 200% tariff will change the fundamental math,” Elms said, adding that nearly all the inputs would still come from abroad. A major bottleneck is the reliance on active pharmaceutical ingredients. Chinese firms currently dominate the upstream supply of these critical components, such as amoxicillin and heparin. Consequently, even if domestic plants are built, they would remain tethered to foreign supply lines for raw materials.
The reliance on active pharmaceutical ingredients has long been a national security concern for U.S. lawmakers, yet untangling those deep trade ties presents its own formidable hurdles. Without a domestic source for basic chemical precursors, the tariff strategy may simply shift dependency from finished generic drugs to the raw materials required to make them.
Impact on India Pharma Exports
The stakes are particularly high for India pharma exports. Indian companies supply nearly 50% of all generic medicines consumed in America, and the U.S. accounts for about a third of India’s total pharmaceutical exports. Arpit Chaturvedi, South Asia advisor at Teneo, warns that the announced generic drug tariffs substantially raise long-term risk for Indian drugmakers despite the two-year reprieve. The pharmaceutical sector is one of India’s largest net export earners, and a full implementation of Trump’s stated tariffs would deal a serious blow to the country’s overall trade balance.
Because margins on ordinary generics are already razor-thin, manufacturers may simply exit specific products if wholesalers refuse to absorb the added costs, rendering them no longer commercially viable. Washington will also find it difficult to simply displace India as a supplier, Chaturvedi noted, given the entrenched manufacturing capabilities and cost efficiencies that Indian firms have developed over decades.
Trump Drug Pricing and Patented Medicines
Meanwhile, Trump drug pricing strategies for patented and branded medicines remain on a separate track. Tariffs on patented pharmaceutical products and ingredients will stay unchanged, following a 100% levy imposed under Section 232 on April 2. Larger drugmakers were given 120 days before that rate takes effect, while smaller contract manufacturers have 180 days.
More than a dozen major companies, including Eli Lilly, Pfizer, and Novo Nordisk, have already struck deals under the president’s “most favored nation” policy. This initiative ties U.S. prices to cheaper international rates and exempts the companies from tariffs for three years. The policy creates a tiered landscape where brand-name giants secure exemptions through pricing agreements, while generic suppliers face the brunt of tariff threats.
What Happens Next
The two-year runway before the 100% tariff hits in 2028 offers a critical negotiating window. New Delhi is expected to push for tariff relief in ongoing trade talks, potentially by pledging corporate investment commitments in the U.S. Since the steepest penalties do not bite until 2028—a U.S. election year—there is hope in India that the rule may never be fully implemented.
In the interim, Indian drugmakers will likely lobby Washington for exemptions, pursue additional Food and Drug Administration approvals, seek contract-manufacturing deals, and accelerate diversification into new global markets to mitigate the threat to India pharma exports. The coming months will reveal whether the threat of 200% tariffs actually breaks ground on new U.S. facilities or simply triggers a wave of corporate lobbying and strategic market shifts.
— Maya Chen, business desk, AXO News